Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Regorafenib is a novel multikinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced gastrointestinal stromal tumors (GISTs). Hypertension is one of the major adverse events of this agent, but to date the incidence and risk of hypertension with regorafenib have not been systematically investigated. We have conducted a systematic review and meta-analysis of published clinical trials to determine its overall incidence and risk.
Methods: PubMed, Web of Science and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies published up to September 9, 2013. Eligible studies were prospective phase II or III clinical trials using regorafenib in cancer patients with data on hypertension available. The incidence and relative risk (RR) of hypertension were calculated using a random-effects model.
Results: Data from a total of 1,069 patients (regorafenib n = 750; controls n = 319) from five clinical trials were included for analysis. The overall incidence of all-grade and high-grade hypertension were 44.4 % [95 % confidence interval (CI) 30.8-59.0 %) and 12.5 % (95 % CI 5.2-27.1 %), respectively. The use of regorafenib in cancer patients was associated with a significantly increased risk of all-grade (RR 3.76, 95 % CI 2.35-5.99) and high-grade (RR, 8.39, 95 % CI 3.10-22.71) hypertension. The risk might vary with tumor types (P = 0.000).
Conclusions: Patients with cancer receiving regorafenib have a significantly higher risk of developing hypertension. Close monitoring and appropriate management of this hypertension are strongly recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-013-1598-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology.
J Nephrol
September 2025
Nephrology and Dialysis Unit, ASL Nord Ovest Toscana, Livorno, Italy.
Hypertension is a clinical condition associated with an increase in cardiovascular morbidity and mortality. In chronic kidney disease (CKD), hypertension is also a driver of faster disease progression. Correct and appropriate treatment with antihypertensive medication reduces the risk of cardiovascular events and slows kidney disease progression.
View Article and Find Full Text PDFG20 stroke burden 1990-2035: trends, projections and precision health insights.
Neurol Sci
September 2025
School of Public Health, Shaanxi University of Chinese Medicine, Shaanxi, 712046, Xianyang, P. R. China.
Background: Stroke persists as the second leading global cause of mortality and disability. We analyzed G20 nations using Global Burden of Disease (GBD) 2021 data (1990-2021) to provide a new perspective.
Methods: We obtained age-standardized rates (ASR) of stroke mortality, incidence, prevalence, and YLLs (years of life lost) across G20 nations.
Impact of Metabolically Healthy and Unhealthy Obesity on Outcomes of Sepsis Complicated by Septic Shock in Elderly Patients.
J Intensive Care Med
September 2025
Independent Researcher, Outcomes Research, Atlanta, GA, USA.
Purpose: Obesity is a risk factor for sepsis complications in older adults. We assessed the impact of metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO) on outcomes in septic shock.
Methods: We conducted a retrospective analysis using the National Inpatient Sample (2016-2020) to identify a cohort of 1,737,075 patients aged 65 years and older who were hospitalized with septic shock, as defined by ICD-10 diagnosis codes.
Arterial Stiffness in HFpEF: From Clinical Insight to Bedside Action.
Cardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFThe Relationship Between the CHA2DS2-VASc Score and Lesion Complexity and Long-Term Outcomes in Peripheral Arterial Disease.
Turk Kardiyol Dern Ars
September 2025
Department of Cardiology, Dicle University School of Medicine, Diyarbakır, Turkiye.
Objective: Originally designed to evaluate stroke risk in individuals with atrial fibrillation unrelated to valvular disease, the CHA2DS2-VASc score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, prior Stroke/transient ischemic attack/systemic embolism, Vascular disease, Age 65-74 years, and Sex category - female) is now additionally utilized for the prognostic evaluation of cardiovascular diseases. This study aimed to evaluate the predictive role of the CHA2DS2-VASc score for lesion severity and long-term survival outcomes in individuals with peripheral artery disease (PAD).
Method: This retrospective analysis included 784 patients diagnosed with PAD via computed tomography (CT) angiography, consecutively enrolled from two medical centers.